National Bank of Canada
COGT icon

National Bank of Canada’s Cogent Biosciences COGT Stock Holding History

National Bank of Canada’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$11 – 2979
2024
Q3 		$11 Buy
+1
New +$10 ﹤0.01% 2690

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

National Bank of Canada's COGT Position: Q4 2024 in Review

National Bank of Canada sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 1 share — an estimated $11 sold.

National Bank of Canada first reported a position in COGT in Q3 2024 and held it in 1 quarter. The position peaked at $11 in Q3 2024. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • National Bank of Canada reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 1 Cogent Biosciences share in Q4 2024, an estimated $11.
  • National Bank of Canada first reported a position in Cogent Biosciences in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's Cogent Biosciences position peaked at $11 in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.